RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
169.00
-8.50 (-4.79%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close177.50
Open174.90
Bid168.70 x 400800
Ask169.00 x 100
Day's Range169.00 - 178.30
52 Week Range157.00 - 403.00
Volume318,165
Avg. Volume217,965
Market Cap360.712M
Beta0.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters12 days ago

    BRIEF-Swire Pacific Announces Sale Of Residential Unit For HK$120 Million By Redhill Properties

    April 9 (Reuters) - Swire Pacific Ltd: * TO SELL RESIDENTIAL UNIT FOR HK$120 MILLION * CO EXPECTED TO RECORD ATTRIBUTABLE GAIN ON DISPOSAL ABOUT HK$29.1 MILLION * PROPERTY SALE CARRIED OUT THROUGH PROPERTY ...

  • Reuters24 days ago

    Sainsbury's needs year's notice to act on post-Brexit trade deal

    Sainsbury's (SBRY.L), Britain's No.2 supermarket group, needs at least a year's notice to figure out how it would deal with new European Union-UK trading arrangements that would come into play when the Brexit transition period ends, its boss said on Tuesday. Last week, EU leaders approved a transition period to help business adapt after Brexit, allowing talks to start next month on the bloc's future trading relationship with Britain. "Effectively the can's been kicked down the road by 21 months," Sainsbury's Chief Executive Mike Coupe told reporters during a tour of its store in Redhill, southern England.

  • RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher
    Zacks3 months ago

    RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher

    RedHill Biopharma (RDHL) was a big mover last session, as the company saw its shares rise more than 10% on the day.

  • American City Business Journals4 months ago

    RedHill teams with Mayo Clinic, MD Anderson on new cancer trial

    Tel-Aviv, Israel-based RedHill Biopharma (RDHL) – which is continuing to build up its U.S. commercial operations based in Raleigh – is teaming with the Mayo Clinic and The University of Texas MD Anderson Cancer Center on a new cancer trial. The new Phase IIa study is for YELIVA – a product candidate RedHill acquired from Apogee Biotechnology back in 2015 – for the treatment of cholangiocarcinoma, or bile duct cancer.

  • American City Business Journals5 months ago

    RedHill grows revenue in third quarter, closes public offering

    According to Tel-Aviv-based RedHill – which opened an office in Raleigh earlier this year with a number of former Salix employees to serve as its head of U.S. commercial operations – its third quarter revenue is from its two initial commercial products, Donnatal and EnteraGam, as well as a third product, Esomeprazole Strontium Delayed-Release (DR) Capsules, which it launched in September . “We expect a decrease in quarterly cash burn rate along with continued revenue growth in 2018,” stated Micha Ben Chorin, chief financial officer of RedHill.

  • RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : November 1, 2017
    Capital Cube6 months ago

    RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : November 1, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for RedHill Biopharma Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
    Zacks6 months ago

    Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics

    Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics

  • American City Business Journals6 months ago

    RedHill lands new orphan drug designation, looks to grow commercial portfolio

    Benefits of the designation include development incentives and tax credits, as well as potentially a prescription drug user fee waiver and seven-year exclusive marketing period, if MESUPRON is ultimately approved.

  • Reuters7 months ago

    RedHill Biopharma's bowel syndrome drug data fails to impress investors

    RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower. The drug, however, did not show statistical significance in improving abdominal pain and overall response in patients - secondary goals in the study. "The study was not designed or meant to show significance in the secondary endpoints ... the results are actually good according to the small sample size," RedHill's Chief Executive Dror Ben-Asher told Reuters.

  • RedHill Biopharma Ltd (RDHL): How Does It Impact Your Portfolio?
    Simply Wall St.7 months ago

    RedHill Biopharma Ltd (RDHL): How Does It Impact Your Portfolio?

    If you are a shareholder in RedHill Biopharma Ltd’s (NASDAQ:RDHL), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : September 20, 2017
    Capital Cube7 months ago

    RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : September 20, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for RedHill Biopharma Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Is RedHill Biopharma Ltd (RDHL) Undervalued?
    Simply Wall St.7 months ago

    Is RedHill Biopharma Ltd (RDHL) Undervalued?

    RedHill Biopharma Ltd (NASDAQ:RDHL), a pharmaceuticals, biotechnology and life sciences company based in Israel, saw significant share price volatility over the past couple of months on the NasdaqCM, rising toRead More...

  • Capital Cube8 months ago

    RedHill Biopharma Ltd. – Value Analysis (TEL AVIV:RDHL) : August 30, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives RedHill Biopharma Ltd. a score of 43. Our analysis is based on comparing RedHill Biopharma Ltd. with the following peers – Compugen Ltd., Kamada Ltd, XTL Biopharmaceuticals Ltd. and BioCancell Ltd. (CGEN-IL, KMDA-IL, XTLB-IL and BICL-IL). Investment Outlook RedHill Biopharma Ltd. has a fundamental score of 43 ... Read more (Read more...)

  • Reuters10 months ago

    RedHill Bio's gastric drug succeeds in late-stage study

    Israel-based RedHill Biopharma Ltd said its experimental drug for the treatment of gastroenteritis met the main goal in a late-stage study. Gastroenteritis is the inflammation of the stomach and intestines that causes vomiting and diarrhea. Bekinda is a once-daily oral pill formulation of the existing anti-nausea drug ondansetron and is designed to provide relief from nausea and vomiting symptoms for a 24-hour period.

  • RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : May 25, 2017
    Capital Cube11 months ago

    RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : May 25, 2017

    Categories: Europe Stock Alerts Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for RedHill Biopharma Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Capital Cubelast year

    RedHill Biopharma Ltd. – Value Analysis (TEL AVIV:RDHL) : May 4, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives RedHill Biopharma Ltd. a score of 43. Our analysis is based on comparing RedHill Biopharma Ltd. with the following peers – Compugen Ltd., Kamada Ltd, XTL Biopharmaceuticals Ltd. and BioCancell Ltd. (CGEN-IL, KMDA-IL, XTLB-IL and BICL-IL). Investment Outlook RedHill Biopharma Ltd. has a fundamental score of 43 ... Read more (Read more...)